between increased expression of IGF-1R and malignant behavior regardless the age at diagnosis and the genetic etiology. IGF-1R labeling was mostly weak in primary tumors from patients with non-metastatic pheo/pgl. Conversely, intense IGF-1R labeling was predominant in cases of pheo/pgl with confirmed metastatic disease. The risk of metastases was 11.7 times higher if tumor IGF-1R labeling was intense independently of age at diagnosis. The probability of remaining free of metastases was higher in patients with pheo/pgl scored weak for IGF-1R at 60 months and more than two fold higher at 120 months of follow-up than in patients with intense IGF-1R labeling in their primary tumors. Conclusions: Our results strongly suggest that IGF-1R is associated with malignancy in familial pheo/pgl and that IGF-1R expression in the primary tumor might be a useful tool to detect those patients harboring pheo/pgl that have an increased risk of metastasis.
INTRODUCTION
Pheochromocytomas (pheo), that derive from chromaffin cells in the adrenal medulla, and paragangliomas (pgl) , that arise from extra-adrenal chromaffin tissue, are tumors that synthesize, store, metabolize and secrete catecholamines. FP/TMEM127, SDHAF2, KIF1B beta and MAX genes have been described in familial and sporadic pheo/pgl [6] [7] [8] [9] .
Although mostly benign, up to 26% of pheo/pgl tumors have been reported as malignant 10 .
Malignancy in pheo/pgl is assessed based on the appearance of distant metastasis where the chromaffin tissue is normally absent 11 . The greater risk of malignancy has been reported in extra-adrenal sympathetic pgl 10 . Moreover, SDHB-related sympathetic pgl has shown to bear the highest risk for malignancy, representing more than 50% of malignant pheo/pgl reported 12 .
Several arguments are in favor of an implication of epithelial-mesenchymal transition (EMT) in pheochromocytoma and paraganglioma malignancy. EMT is a physiologic process that normally contributes to the development of the embryo and may contribute to the development of certain pathological conditions such as fibrosis and cancer 13 . A recent study also revealed that EMT is specifically induced in succinate dehydrogenase subunit B (SDHB)-related metastatic Increased IGF-1R expression has been shown during progression to metastatic phenotypes of
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© 2013 Blackwell Publishing Ltd several types of cancer 15 . The role of the IGF family ligands, has also been shown in some experimental models with regard to the induction of EMT. Recently, it was also shown that constitutively active IGF-1R causes cell transformation and EMT in a normal epithelial breast cell line, which is significant, as relatively few oncogenes, when expressed alone, have been shown to cause in vivo tumorigenic potential in MCF10A cells 17 .
Based on these evidences, we hypothesize that IGF-1R expression is higher in malignant compared to benign familial pheo/pgl. To test this hypothesis, we analyzed, by immunohistochemistry, the expression of IGF-1R in primary tumors from patients harboring pheo/pgl of different genetic origin and degree of malignancy. Samples from the primary tumors were evaluated for IGF-1R labeling by 2 observers blinded to the clinical diagnosis, and given an alphanumeric code to assure patient's confidentiality.
PATIENTS AND METHODS
For each sample, tumor immunohistochemistry was compared in the same slide with normal adrenal tissue obtained from autopsy within 3 hours after death to avoid overt autolysis and deterioration of immunoreactivity and/or receptor protein.
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IGF-1R Immunohistochemistry:
Tumor samples were fixed in 10% neutral formaldehyde and paraffin embedded; 5-μm thick sections were stained with hematoxilin and eosin. Each slice of tumor was mounted on charged glass slides along with normal adrenal tissue, as an internal control and for comparative purposes. Sections were dewaxed in xylene, rehydrated, and endogenous peroxidase blocked with 3% H 2 O 2 . Antigen retrieval was carried out in a microwave oven for 3 min in 0.01 M (pH = 6.0) citrate buffer. Nonspecific binding was blocked with Tris-buffered saline containing 1% bovine serum albumin. The rabbit polyclonal primary antibody against the IGF-1R (1:500 in Trisbuffered saline) was from Santa Cruz (Santa Cruz, CA, USA) 20 . Antibody-antigen binding was detected using appropriate biotinylated secondary antibodies followed by addition of peroxidase-conjugated streptavidin (Ready-to-use streptavidin-peroxidase LSAB+System-HRP DAKO, Carpinteria, CA, USA).
Sites of peroxidase activity were demonstrated using 3,3'-diaminobenzidine (Liquid DAB+, DAKO, Carpinteria, CA, USA). Slides were counterstained with hematoxylin for 30 sec. The cellular distribution of IGF-1R was assessed using an optic microscope. specimens were subjected to quantitative Real time PCR assays (qRT-PCR) using EvaGreen as intercalating dye. The qRT-PCR was performed in a Rotor Gene 6000 cycler. In all cases, experiments were done in duplicate. Negative controls for cDNA synthesis and PCR procedures were included in all cases. Primer specificity: a Rotor-Gene 6000 melting curve analysis was performed, which for both
IGF-1R

Accepted Article
© 2013 Blackwell Publishing Ltd primer sets resulted in single product-specific melting curves. Gel electrophoresis and a melting curve analysis of PCR products showed that no primer-dimers were generated during the runs. The levels of IGF-1R were studied and β-actin was selected as housekeeping gene. The total expression ratio of IGF-1R was tested for significance by a randomization test implemented in the relative expression software tool (REST) (www.gene-quantification.info) 21 , which is an Excel-based Statistical Analysis: Sample size calculation was performed to establish the least number of specimens to be evaluated in order to detect a difference in the proportion of cases with malignant evolution between intense and weak IGF-1R labeling. Using a bilateral test, a sample size of 9 specimens per group was considered sufficient to detect a difference with a 99% confidence level and a 90% power, based on an estimated proportion of 10% malignancy evidenced at 5 yr of follow- 
RESULTS
Forty specimens, corresponding to 40 patients with a median age at diagnosis of 16 years (range 4-70 years) were analyzed. Sixteen patients harbored VHL disease, 10 had familial SDH mutation-related tumors (9 SDHB and 1 SDHD) and 8 MEN 2 (6 MEN2A and 2 MEN2B). The remaining 6 patients had negative genetic studies. Malignant disease was confirmed in 11 of the 40 patients. In 3 out of 40 patients recurrences were documented. The distribution of the IGF-1R labeling of all 40 processed specimens according to the diagnosis of metastatic or non-metastatic disease is summarized in Table 2 Figure 2) . Also, the probability of remaining free of metastases was higher in patients with pheo/pgl scored weak for IGF-1R at 60 months and more than two fold higher at 120 Four tumors from patients with negative genetic tests were intense for IGF-1R labeling, and two of these patients had metastatic disease and died from causes related to the pheo.
All 3 patients with recurrent pheo, belonged to the VHL group; 2 patients had tumors with weak IGF-1R labeling and one of them died (case #15) from causes unrelated to the pheo. The third case (case #4) had a tumor with intense IGF-1R labeling and died from causes related to the pheo.
DISCUSSION
Our data show that intense IGF-1R labeling in primary pheo/pgl was associated with almost 12 fold increased risk of metastases, regardless the age at diagnosis and genetic background. As already reported, malignancy was more frequently found in tumors from SDHB patients. Conversely, weak IGF-1R labeling was more prevalent in tumors from VHL patients, who showed a more benign outcome.
Although increased expression of the IGF-1R has been associated with worse prognosis in several types of cancer, some reports have shown otherwise, in particular regarding breast and prostate cancer 22;23 , where a decreased expression of the IGF-1R is observed in malignant lesions compared to the normal epithelium. Recently, it has been showed that the IGF-1R expression in benign human pheo cells is higher than in normal adrenal medulla 24 . The present study is the first to report a significant overexpression of the IGF-1R in primary human pheo/pgl with malignant behavior compared to benign tumors. In our series, 10 out of 11 tumors from patients with documented metastases showed an intense IGF-1R labeling. Moreover, a worse outcome of pheo/pgl patients was associated with intense IGF-1R expression levels as is shown by Kaplan Meier analysis. Conversely, patients with weak IGF-1R tumor labeling have 1.5 times the probability to remain free of metastasis at 5 years after surgery than
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At present the only treatment for pheo/pgl is surgery. Besides, there are no histological features to definitively identify or predict the outcome of pheo/pgl patients. Malignant behavior can be currently defined only by the appearance of metastasis. Several markers, such as COX and Bcl2, MIB-1, p53, VEGF and SNAIL among others [25] [26] [27] [28] [29] , or histological features (PASS score) 30 have been proposed as potential predictors of malignancy of pheo/pgl, but results have been inconclusive. For example, SNAIL expression had a 100% sensitivity of detecting the malignant tumors. However, by this method, the specificity was only 56%. A recent report 31 proposed methoxytyramine as a new biomarker of metastatic pheochromocytoma and paraganglioma, with a calculated diagnostic sensitivity of only 57%, but with a specificity of 85%. In our study, IGF-1R expression had 91% sensitivity of detecting malignant tumors, while the specificity was 62%. While the majority of cases have a long follow-up period, there are some with only short follow-up. Thus, the absence of malignancy in these cases cannot be taken for granted. However, this bias would tend to decrease the difference in the proportion of intense labeling between malignant and benign cases and to decrease the diagnostic specificity. In fact, in 6 of 10 cases with high intensity and no documented metastases, the follow-up is less than 5 yr. A longer follow-up eventually detecting more malignant cases would increase the proportion of true positives. Therefore, our analysis is conservative and does not overestimate our conclusions.
One limitation of this study is that our series has a large proportion of young patients, probably due to the fact that familial cases usually present at younger ages. However, it should be noted that our patients were all index cases that guided the familial studies and not selected from screening programs. Furthermore, we used a Cox regression analysis to adjust for age at diagnosis, which allowed us to rule out the age at diagnosis as a confounding variable in the analysis. Another peculiarity of our study is the high proportion of malignant cases in patients with MEN2, probably due
© 2013 Blackwell Publishing Ltd to a disproportionate referral of patients with metastases to our center. Since our objective was not to estimate the prevalence of malignancy in subjects with MEN2, our sample of MEN2 patients was small (8 cases), thus inadequate to make such estimation.
Overexpression of IGF-1R promotes neoplastic growth 32 37 . Mutations of the SDH subunits are associated with a higher incidence of extra-adrenal pheo, and malignancy is frequent in SDHB but rare in VHL associated pheo 12 . Accordingly, in our group of patients with SDH mutations tumors were mostly extra-adrenal, malignant and were associated with an intense labeling for the IGF-1R, and tumors from our group of VHL patients were mostly benign and had a positive weak staining for the IGF-1R. The mechanisms responsible for enhanced IGF-1R expression in pheo/pgl associated to hereditary syndromes and other malignancies are still unclear. Overexpression of the IGF-1R in our group of pheo/pgl was related to malignancy irrespective of the genetic etiology. This suggests that mechanisms other than those related to the development of pheo/pgl in these syndromes are responsible for the higher expression of the IGF-1R in the subset of malignant tumors.
Our results strongly suggest that immunolabeling for the IGF-1R is associated with malignancy in familial pheo/pgl and might be a useful tool to predict the adverse outcome of pheo/pgl patients.
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